Incretin research has followed a clear trajectory: from single-receptor agonism to dual, and now to triple. Retatrutide sits at the frontier of that progression. It is an investigational peptide designed to activate three separate metabolic receptor systems — GIP, GLP-1, and glucagon — in a single molecule. Phase 2 clinical data has placed its weight-loss findings beyond what had been previously reported for any pharmacological agent, drawing significant attention from researchers working in obesity, metabolic disease, and endocrinology.
Retatrutide is not approved by the FDA, EMA, or Health Canada. It remains in clinical development with no brand name. BME Health supplies retatrutide as a research compound for laboratory purposes only.
1. What Is Retatrutide?
Retatrutide (also designated LY3437943) is a synthetic peptide developed by Eli Lilly as an investigational drug. It is distinguished from all currently approved incretin agents by its triple-receptor activity: an agonist at the GIP receptor, the GLP-1 receptor, and the glucagon receptor simultaneously.
GLP-1 and GIP are the incretin targets — the same systems activated by semaglutide and tirzepatide. The glucagon receptor is the addition: traditionally associated with raising blood glucose, but in the context of a triple agonist, glucagon receptor activity is thought to contribute additional energy-expenditure and liver fat metabolism effects that GLP-1 and GIP agonism do not fully capture.
Retatrutide's half-life is approximately six days, supporting once-weekly dosing. A Phase 2 overview in PubMed provides a mechanistic and clinical summary.
2. Why Retatrutide Gets So Much Attention
In a Phase 2 obesity trial published in the New England Journal of Medicine, adults with obesity receiving retatrutide 12 mg weekly lost an average of approximately 24.2% of their body weight by 48 weeks. For context, tirzepatide's SURMOUNT-1 highest dose produced around 20.9% at 72 weeks — not a direct comparison, given different designs and timepoints, but the retatrutide numbers were substantial enough to generate sustained attention in the metabolic research community.
The mechanistic hypothesis behind the headline results is that the glucagon receptor component adds energy-expenditure and liver-fat-clearing effects that GLP-1 and GIP agonism do not fully capture. Retatrutide is also being studied in type 2 diabetes, fatty liver disease, and cardiometabolic risk, with Phase 3 programs underway.
3. Obesity and Weight Management
The foundational evidence comes from the NEJM Phase 2 trial, which enrolled 338 adults with a BMI of 27 or higher without type 2 diabetes. Participants receiving 12 mg weekly showed 24.2% average weight reduction at week 48; lower doses (4 mg and 8 mg) produced dose-dependent reductions of approximately 8.7% and 17.3%. More than half of participants in the highest-dose group achieved at least 24% weight loss. Improvements in waist circumference, blood pressure, fasting glucose, fasting insulin, and lipid parameters were also reported, suggesting broad metabolic effects beyond body weight alone.
4. Type 2 Diabetes and Glycemic Control
A separate Phase 2 trial in adults with type 2 diabetes, published in The Lancet, found dose-dependent HbA1c reductions alongside significant weight loss at higher doses. The combination of glycemic improvement and body weight reduction reinforces the case for triple agonism as an approach to metabolic disease.
5. Liver Disease: MASLD Research
A trial published in Nature Medicine reported significant reductions in liver fat content and histological improvements in steatosis and inflammation in MASLD patients. The glucagon receptor component is specifically hypothesized to contribute here, since glucagon receptor signaling promotes hepatic fatty acid oxidation — a mechanism that GLP-1 and GIP agonism does not directly address.
6. Kidney and Cardiometabolic Findings
Exploratory analyses identified reductions in kidney stress markers and improvements in blood pressure and triglycerides. These findings are preliminary, but consistent with the broad metabolic reach seen in other dual-and triple-agonist compounds. The TRIUMPH-3
cardiovascular outcomes study, registered at ClinicalTrials.gov (NCT05882045), is the large Phase 3 trial designed to examine cardiovascular and obesity-related endpoints.
7. How It Works
Retatrutide's activity runs through three receptor systems.
GLP-1 receptor agonism produces the familiar incretin effects: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and appetite/satiety signaling through hypothalamic and brainstem GLP-1 receptors — the pathway shared with semaglutide and tirzepatide. GIP receptor co-agonism adds pathways that synergize with GLP-1 activity, including adipose tissue effects, as established in tirzepatide's clinical program.
Glucagon receptor agonism is the distinctive addition. Glucagon typically raises blood glucose, but at the doses used in incretin combination approaches, glucagon receptor activation is thought to increase energy expenditure and enhance hepatic fatty acid oxidation (potentially explaining the pronounced MASLD findings). Managing this component carefully — preserving its energy-expenditure contributions while the simultaneous GLP-1 and GIP activity limits glucose-raising effects — is a central design challenge for triple agonists, as reviewed in PubMed literature.
A C18 fatty diacid modification supports albumin binding and extends the half-life to approximately six days.
8. What Researchers Are Still Learning
Phase 2 data in obesity, type 2 diabetes, and liver disease has been published, but Phase 3 trials are ongoing and the full picture on long-term safety, cardiovascular outcomes, and durability of effect is not yet available.
The glucagon receptor component raises the most active mechanistic questions. The precise mechanisms by which glucagon co-agonism works in the context of full GIP/GLP-1 co-agonism are still being characterized, and whether the current glucagon dose is optimally tuned is a question Phase 3 data may help address. Side-effect profiles in Phase 2 were consistent with other incretin agents: gastrointestinal effects (nausea, vomiting, diarrhea) were most common, with increased heart rate at higher doses.
Whether benefits persist after stopping treatment has not been studied in dedicated discontinuation trials for retatrutide. Given the pattern seen with semaglutide and tirzepatide, researchers expect similar dynamics, but confirmatory data is pending.
For broader context, see the cagrilintide-semaglutide combination (CagriSema), and investigational agents like mazdutide and survodutide that represent alternative receptor-targeting designs.
9. How Retatrutide Compares to Related Compounds
Retatrutide represents the current frontier of receptor-expansion strategy in incretin research.
Semaglutide acts on GLP-1 receptors only, establishing the modern standard for pharmacological weight loss and demonstrating cardiovascular benefit in large outcomes studies. Tirzepatide adds GIP co-agonism and produced meaningfully greater weight loss than semaglutide in head-to-head trials; it is the most direct predecessor to retatrutide in receptor-expansion logic. Retatrutide's Phase 2 data suggests a further step beyond tirzepatide's outcomes, though it remains investigational and the two cannot yet be directly compared from completed Phase 3 data.
Cagrilintide takes a different approach, adding amylin receptor activity rather than glucagon, and being studied in combination with semaglutide as CagriSema. Each successive generation has added receptor activity that, in the data so far, has produced incrementally greater metabolic outcomes. The key open questions are how far the benefits extend, what the long-term safety profile looks like, and whether the effects are durable.
10. Research Status and Sourcing
Retatrutide is not approved by the FDA, EMA, or Health Canada, and is not marketed under any brand name. Phase 3 trials including TRIUMPH-3 (NCT05882045) are active. This distinguishes it from semaglutide and tirzepatide, both of which hold full drug approval in multiple jurisdictions.
Retatrutide is available from BME Health as a research compound, supplied for laboratory use only.
This article is for educational and research purposes only and is not medical advice.
11. Frequently Asked Questions
What is retatrutide? Retatrutide (LY3437943) is an investigational synthetic peptide and triple hormone receptor agonist that activates the GIP, GLP-1, and glucagon receptors simultaneously in a single molecule.
How does retatrutide work? Retatrutide activates GLP-1 receptors (insulin secretion, glucagon suppression, satiety signaling), GIP receptors (incretin effects and adipose tissue signaling), and glucagon receptors (energy expenditure and hepatic fatty acid oxidation). Managing the glucagon component to preserve energy-expenditure benefits while limiting glucose-raising effects is a key design challenge, as described in PubMed triple agonist reviews.
What conditions has retatrutide been studied for? Published Phase 2 research covers obesity and weight management, type 2 diabetes, and MASLD (metabolic dysfunction-associated steatotic liver disease). Exploratory data on kidney parameters and cardiometabolic risk factors has also been reported, with Phase 3 trials including cardiovascular outcomes now active.
How does retatrutide compare with tirzepatide or semaglutide? Phase 2 data placed retatrutide's average weight-loss percentages above those reported for tirzepatide and semaglutide, with glucagon receptor activity hypothesized to contribute additional energy-expenditure effects. No head-to-head trials have been published. Both semaglutide and tirzepatide are approved drugs; retatrutide remains investigational.
What are the side effects seen in retatrutide studies? The most common adverse events in Phase 2 trials were gastrointestinal (nausea, vomiting, diarrhea, decreased appetite), consistent with other incretin agents. Increased resting heart rate was also observed at higher doses. Full safety data from Phase 3 trials is not yet available.
What is the retatrutide half-life? Retatrutide's half-life is approximately six days in clinical trial data. This pharmacokinetic profile, achieved through fatty acid conjugation that facilitates albumin binding, supports once-weekly dosing in the ongoing clinical programs.
Is retatrutide approved by the FDA? No. Retatrutide has not received approval from the FDA, EMA, Health Canada, or any other major regulatory authority. It remains investigational, with Phase 3 trials ongoing. Unlike semaglutide and tirzepatide, there is no approved brand-name product.
Is retatrutide still in clinical trials? Yes. Phase 3 trials are active, including the TRIUMPH-3 study (ClinicalTrials.gov NCT05882045). Phase 2 results in obesity, type 2 diabetes, and MASLD have been published; Phase 3 outcomes data is still developing.
12. References
1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for
Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. http://www.nejm.org/doi/10.1056/ NEJMoa2301972
2. Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor
agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled phase 2 trial. Lancet. 2023;402(10401):529–544. https://linkinghub.elsevier.com/retriev e/pii/S014067362301053X
3. Sanyal AJ, et al. Retatrutide in metabolic dysfunction-associated steatohepatitis. Nature
Medicine. 2024. https://www.nature.com/articles/s41591-024-03018-2
4. ClinicalTrials.gov. TRIUMPH-3: A Study of Retatrutide in Adults with Obesity and
Cardiovascular Disease (NCT05882045). https://clinicaltrials.gov/study/NCT05882045
5. Boer GA, Holst JJ. Incretin Hormones and Type 2 Diabetes — Mechanistic Insights and
Therapeutic Approaches. Biology. 2020. PMC review on triple agonists and incretin research. https://pmc.ncbi.nlm.nih.gov/articles/PMC10901658/
6. PubMed: Phase 3 type 2 diabetes study for retatrutide. https://pubmed.ncbi.nlm.nih.gov/422505
75/
Shop this compound
Documented, batch-tested, and supplied for research use only.
